59690-89-0

Basic information

• Product Name: N-(4-Aminophenyl)propanamide
• Synonyms: AKOS BB-8167;LABOTEST-BB LT00511959;ASISCHEM T31165;P-AMINO PROPIONANILIDE;N-(4-AMINOPHENYL)PROPANAMIDE;4-Aminopropionylanilide;para-Aminopropionylanilide;4-AMINO PROPIONANILIDE
• CAS NO: 59690-89-0
• Molecular Formula: C₉H₁₂N₂O
• Molecular Weight: 164.2
• Mol File: 59690-89-0.mol

Chemical Properties

• Boiling Point: 282.7 °C at 760 mmHg
• Flash Point: 124.8 °C
• Appearance: /
• Density: 1.162 g/cm³
• Vapor Pressure: 0.0033mmHg at 25°C
• Refractive Index: 1.616
• CAS DataBase Reference: N-(4-Aminophenyl)propanamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-Aminophenyl)propanamide(59690-89-0)
• EPA Substance Registry System: N-(4-Aminophenyl)propanamide(59690-89-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 59690-89-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Production:
N-(4-Aminophenyl)propanamide is used as an intermediate in the synthesis of various drugs, including analgesics and anticonvulsants. Its unique structure allows for the development of medications that can effectively target specific conditions and diseases.
Used in Research and Development:
In the scientific community, N-(4-Aminophenyl)propanamide is utilized in research and development for new medications. It aids in understanding biochemical pathways and interactions within the human body, which is crucial for the advancement of medical treatments.
Used in Drug Design and Discovery:
Due to its diverse pharmacological properties, N-(4-Aminophenyl)propanamide is considered a potential target for drug design and discovery. Its unique chemical structure offers opportunities for the creation of innovative therapeutic agents that can address a wide range of health issues.

InChI:InChI=1/C9H12N2O/c1-2-9(12)11-8-5-3-7(10)4-6-8/h3-6H,2,10H2,1H3,(H,11,12)

Upstream product

• 940523-16-0 (4-propionylamino-phenyl)-carbamic acid tert-butyl ester 
• 71026-66-9 N-(tert-butoxycarbonyl)-1,4-phenylenediamine 
• 4850-93-5 N-(4-nitrophenyl)propionamide 
• 79-03-8 propionyl chloride 
• 106-50-3 1,4-phenylenediamine 

Downstream Products

• 1092521-93-1 C₁₂H₁₈N₂O₃S 

Relevant articles and documents

Thiazole ring-containing amide compounds as well as preparation method and application thereof

The invention discloses thiazole ring-containing amide compounds as well as a preparation method and application thereof, and belongs to the field of chemical technologies and pesticides. According to the present invention, p-phenylenediamine is adopted as a raw material to synthesize a series of the thiazole ring-containing amide compounds, and the synthesized thiazole ring-containing amide compounds have good inhibition effects on Xanthomonas oryzae pv.Oryza (Xoo), Xanthomonas oryzae pv.Oryzcola (Xoc) and Xanthomonas axonophora pv.Citri (Xac) in agricultural diseases and insect pests, and can be used for preparing the anti-plant bacterium agent.

Synthesis of ring-opened derivatives of triazole-containing quinolinones and their antidepressant and anticonvulsant activities

Based on the potent antidepressant and anticonvulsant activities of the triazole-containing quinolinones reported in our previous work, a series of ring-opened derivatives of them were designed, synthesized in this work. Their antidepressant and anticonvulsant activities were screened using the forced swimming test (FST) and the maximal electroshock seizure test (MES), respectively. The results showed that compounds 4a, 5a, 6c-6e, 6g-6i, and 7 led to significant reductions in the accumulated immobility time in the FST at a dose of 50 mg/kg. Especially compound 7 exhibited higher levels of efficacy than the reference standard fluoxetine in the FST and the tail suspension test. The results of an open field test excluded the possibility of central nervous stimulation of 7, which further confirmed its antidepressant effect. Meanwhile, compounds 6a-6i and 7 showed different degrees of anticonvulsant activity in mice at the doses range from 300 to 30 mg/kg in the MES. Among them, compounds 6e and 7 displayed the ED50 of 38.5 and 32.7 mg/kg in the MES, and TD50 of 254.6 and 245.5 mg/kg, respectively. No one showed neurotoxicity at the dose of 100 mg/kg. The preliminary investigation forward to their mechanism indicated that regulation of GABAergic system might contribute to their anticonvulsive and anti-depressive action.

Synthesis and Antibacterial Evaluation of N-phenylacetamide Derivatives Containing 4-Arylthiazole Moieties

A series of new N-phenylacetamide derivatives containing 4-arylthiazole moieties was designed and synthesized by introducing the thiazole moiety into the amide scaffold. The structures of the target compounds were confirmed by 1H-NMR, 13C-NMR and HRMS. Their in vitro antibacterial activities were evaluated against three kinds of bacteria-Xanthomonas oryzae pv. Oryzae (Xoo), Xanthomonas axonopodis pv. Citri (Xac) and X.oryzae pv. oryzicola (Xoc)-showing promising results. The minimum 50% effective concentration (EC50) value of N-(4-((4-(4-fluoro-phenyl)thiazol-2-yl)amino)phenyl)acetamide (A1) is 156.7 μM, which is superior to bismerthiazol (230.5 μM) and thiodiazole copper (545.2 μM). A scanning electron microscopy (SEM) investigation has confirmed that compound A1 could cause cell membrane rupture of Xoo. In addition, the nematicidal activity of the compounds against Meloidogyne incognita (M. incognita) was also tested, and compound A23 displayed excellent nematicidal activity, with mortality of 100% and 53.2% at 500 μg/mL and 100 μg/mL after 24 h of treatment, respectively. The preliminary structure-activity relationship (SAR) studies of these compounds are also briefly described. These results demonstrated that phenylacetamide derivatives may be considered as potential leads in the design of antibacterial agents.

PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS

The present invention provides kinase inhibitors with anti-proliferative activity comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof. In addition, the invention provides methods for making novel compounds and methods for using the compounds.

Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators

A series of amides, structurally related to DM232 (unifiram) and DM235 (sunifiram), characterized by a 1,2,3,4-tetrahydropyrazino[2,1-a]isoindol-6(2H)-one, 1,4-diamino-cyclohexane or 1,4-diaminobenzene ring, have been synthesized and tested for cognition-enhancing activity in the mouse passive-avoidance test. Some of the compounds display good antiamnesic and procognitive activity, with higher potency than piracetam, while some cyclohexane derivatives are endowed with amnesia inducing properties.

Thiourea inhibitors of herpes viruses. Part 1: Bis-(aryl)thiourea inhibitors of CMV

Bis-(aryl)thioureas were found to be potent and selective inhibitors of cytomegalovirus (CMV) in cultured HFF cells. Of these, the thiazole analogue 38 was investigated as a potential development candidate.